Metformin added to insulin therapy for type 1 diabetes mellitus – based on literature and own expe- rience
Keywords:
type 1 diabetes, insulin therapy, additional therapy, metformin, metabolic controlAbstract
Insulin administration is the primary therapy for type I diabetes mellitus (TIDM). Current availa-ble insulin therapies do not successfully enable patients with TIDM to reach glycemic goals without side effects such as hypoglycemia and weight gain. Type 1 diabetes is recognised to include an element of insulin resistance. Insulin resistance is an independent risk factor for the development of macro- and microvascular complications of Type 1 diabetes and may also contribute to the development of the dis-ease. Metformin is a commonly prescribed oral hypoglycaemic agent used to treat type 2 diabetes melli-tus. Addition of metformin to insulin in patients with type 1 diabetes mellitus improves metabolic con-trol. Metformin acts by promoting glucose utilization and reducing hepatic glucose production. In type 1 diabetes, addition of metformin to insulin therapy, to improve insulin sensitivity, reduces insulin-dose requirement. Metformin can contribute towards improving glycaemic control in patients with TIDM.
Downloads
References
Zawada A., Wierusz-Wysocka B.: Zastosowanie metforminy w cukrzycy typu 1. Diabetologia Praktyczna 2009; 10:143–150.
Gottlieb B., Auld W.H.: Metformin in treatment of diabetes mellitus. Br Med J. 1962; 1:680–682.
Pyke D.A.: General treatment of diabetes. Br Med J. 1970; 3:268–269.
Ungar G., Freedman L., Shapiro Sl.: Pharmacological studies of a new oral hypoglycemic drug. Proc Soc Exp Biol Med. 1957; 95,190–192.
Vigneri R., Goldfine I.D.: Role of metformin in treatment of diabetes mellitus. Diabetes Care. 1987; 10:118–122.
DeFronzo R.A., Goodman A.M.: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995; 333:541–549.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. [No authors listed]. Lancet. 1998; 352:854–865.
UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. [No authors listed]. Diabetes Care. 1998; 21:87–92.
Czyżyk A., Ławecki J., Sadowski J., Ponikowska I., Szczepanik Z.: Effect of biguanides on intestinal absorption of glucose. Diabetes. 1968; 17:492–498.
Czyżyk A., Lao B., Bartosiewicz W., Szczepanik Z., Orłowska K.: Porównanie wpływu fenforminy, buforminy i metforminy na poziom mleczanu we krwi. Pol Arch Med Wewn 1978; 59:241–254
Otto-Buczkowska E.: Spostrzeżenia kliniczne dotyczące zastosowania doustnych leków hipoglikemizujących u dzieci z cukrzycą. Pol.Tyg.Lek. 1973; 28:904–907.
Otto-Buczkowska E., Kokot F., Kuska J.: Cukrzyca o łagodnym przebiegu u dzieci. Przegl.Lek. 1975; 32:641–646.
Tatoń J., Kowalik-Borówka E.: Wskazania i przeciwwskazania do leczenia cukrzycy pochodnymi biguanidu w świetle badań metabolicznych i epidemiologicznych. Przegl Lek 1979; 36:553–557
Gin H., Slama G., Weissbrodt P., Poynard T., Vexiau P., Klein J.C., Tchobroutsky G.: Metformin reduces post-prandial insulin needs in type I (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia. 1982; 23:34–36.
Gin H., Messerchmitt C., Brottier E., Aubertin J.: Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism. 1985; 34:923–925.
Hermann L.S.: Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab. 1979; 5:233–245.
Pagano G., Tagliaferro V., Carta Q., Caselle M.T., Bozzo C., Vitelli F., Trovati M., Cocuzza E.: Metformin reduces insulin requirement in Type 1 (insulin-dependent) diabetes. Diabetologia. 1983; 24:351–354.
Araszkiewicz A., Uruska A., Zozulinska-Ziolkiewicz D., Pilacinski S., Wierusz-Wysocka B.: Factors related to insulin resistance in type 1 diabetic patients treated with intensive insulin therapy from the onset of the disease. Diabetes Res Clin Pract. 2010 Jun 9. [Epub ahead of print]
Uruska A., Araszkiewicz A.: Insulinooporność w cukrzycy typu 1 Endokrynol Diabetol. Chor Przemiany Materii Wieku Rozw 2009; 15(2):119–123.
Pang T.T., Narendran P.: Addressing insulin resistance in Type 1 diabetes. Diabet Med. 2008; 25:1015–1024.
Moon R.J., Bascombe L.A., Holt R.I.: The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes. Metab. 2007; 9:143–145.
Gabbay M.A.: [Adjunctive therapies to glycaemic control of type 1 diabetes mellitus]. Arq Bras Endocrinol Metabol. 2008; 52:279–287.
Jacobsen I.B., Henriksen J.E., Beck-Nielsen H.: The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol. 2009; 105:145–149.
Khan A.S., McLoughney C.R., Ahmed A.B.: The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. Diabet Med. 2006; 23:1079–1084.
Lund S.S., Tarnow L., Astrup A.S., Hovind P., Jacobsen P.K., Alibegovic A.C. i wsp.: Effect of adjunct metformin treatment in patients with type–1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One. 2008; 3(10):e3363.
Vella S., Buetow L., Royle P., Livingstone S., Colhoun H.M., Petrie J.R.: The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010; 53:809–820.
Lund S.S., Tarnow L., Astrup A.S., Hovind P., Jacobsen P.K., Alibegovic A.C. i wsp.: Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab. 2009; 11:966–977.
Schatz H.: Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Diabetologia. 2010; 53:2264–2265.
Aronfy A.G.: The use of DBI in diabetic children: case presentation and discussion. Clin Proc Child Hosp Dist Columbia. 1962; 18:95–108.
Barta L.: [Biguanidin preparations in the treatment of diabetes mellitus in children.] Gyermekgyogyaszat. 1962; 13:1–9.
Dituri B., Mosier H.D.: Placebo-controlled study with phenformin (DBI) in diabetic children. J Am Med Womens Assoc. 1961; 16:939–941.
Ferguson A.W., De La Harpe Pl., Farquhar J.W. : Dimethyldiguanide in the treatment of diabetic children. Lancet. 1961; 1:1367–1369.
Grégoire J., Lestradet H.: [Association of phenformin with insulin therapy in treatment of diabetes in children and adolescents] Journ Annu Diabetol Hotel Dieu. 1969; 10:427–429.
Lestradet H., Besse J., Billaud L.: [Study of the action of a biguanide (N,N-dimethylguanylguanidine) on a group of 235 diabetic children.] Presse Med. 1960; 68:391–393.
Schatz H., Winkler G., Jonatha E.M., Pfeiffer E.F.: Studies on juvenile--type diabetes in children. Assessment of control under treatment with constant and variable doses of insulin with or without addition of biguanides. Diabete Metab. 1975; 1:211–220.
American Diabetes Association. Type 2 diabetes In children and adolescents (Consensus Statement). Diabetes Care 2000; 23,381–389.
Hamilton J., Cummings E., Zdravkovic V., Finegood D., Daneman D.: Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care. 2003; 26:138–143.
Otto-Buczkowska E., Nowowiejska B., Jarosz-Chobot P., Stańczyk J.: Czy doustne leki przeciwcukrzycowe znajdują zastosowanie w leczeniu młodocianych chorych z różnymi postaciami cukrzycy i stanami insulinooporności?, Przegl Lek 2009; 66:388–393.
Sarnblad S., Kroon M., Aman J.: Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003; 149:323–329.
Urakami T., Morimoto S., Owada M., Harada K.: Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus. Pediatr Int. 2005; 47:430–433.
Otto-Buczkowska E., Jarosz-Chobot P., Machnica Ł.: Diabetes mellitus type 1, type 2 or type 1.5 – dilemmas in making proper diagnosis. Diabet Dośw i Klin 2008; 8:91–94.
Otto-Buczkowska E.: Perspektywy zastosowania leków wspomagających w leczeniu cukrzycy. Perspektywy zastosowania leków wspomagających w leczeniu cukrzycy. Lekarz 2009; 13:48–53.
Stańczyk J., Jarosz-Chobot P., Otto-Buczkowska E., Nowowiejska B.: Zastosowanie doustnych leków przeciwcukrzycowych w praktyce pediatrycznej – obserwacje własne. Endokrynol Pol 2008; 59(5):434–445.
Abdelghaffar S., Attia A.M.: Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev. 2009 Jan 21; (1):CD006691.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2010 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
